About us | GEn1E Lifesciences

MEET our Team

The Genies behind GEn1E

Our team has strong domain expertise in developing novel, 1^st-in-class drugs as well as platforms

Ritu Lal, PhD, MS

CEO, Founder and Board Director

Ritu has a track record of 3 FDA approvals in US and in Japan.

Dr. Jeffrey Hasday

Inventor of the p38 technology

Prof. Paul Shapiro

Inventor of the p38 technology

Soujanya Bhumkar, MS

AI/ML Platform

Maya Das, MD

Clinical Development

Nate Larson, PhD

Drug Product

Andrew Sonderfan, PhD, DABT

Toxicology

Beth Stannard, MS, CCRP, CCRC

Clinical Operations

Indraneel Roy, MS

AI/ML Platform

Lassi Lehtovaara, MS

AI/ML Platform

Board of Directors

François Nader, MD

Chairman of the Board

Dr. Nader currently serves as chairman of the board of directors of GEn1E, as board director of Moderna and Ring Therapeutics and as strategic advisor to Blackstone Lifesciences.

Ritu Lal, PhD, MS

CEO, Founder and Board Director

Ritu has 20+ years of Biotech/Pharma leadership experience and has taken drugs from discovery to FDA approval 3 times. She has 60+ publications and is Adjunct Faculty at University of Maryland School of Pharmacy and University of Pacific.

Noor Kamruddin

Board Director

Partner at CLEAR Ventures and Board member of Cartesian Kinetics and GEn1E. Also, Board Observer at Tignis, AICrete, Opsera, and Acante.

Alan Levy, PhD

Board Director

Board member at Intuitive Surgical, Tasso Inc., Holoclara Inc., Bardy, Dx and GEn1E. Previously, CEO at Incline Therapeutics, CEO and President at Northstar Neuroscience; CEO and President at Heartstream; and President at Heart Technology.

Soujanya Bhumkar, MS

Co-founder, AI/ML Platform and Board Director

Soujanya is a chemical engineer with an MBA from the University of Chicago. He co-founded 4 technology startups with successful exits including a major strategic partnership with Google.

Scientific & Tech Advisors

Dr. Nevan Krogan

Dr. Krogan’s lab at UCSF focuses on developing and applying quantitative, systematic proteomic and genetic approaches to study complex biological and biomedical problems.

Dr. Anil Jegga

Dr. Anil’s work is focused on developing and applying methods to integrate the heterogeneous omics and biomedical big data to build better predictive models of disease, drug discovery and repurposing, and drug response.

Dr. David Young

Founder and CEO of Processa Pharma
Founder of GloboMax and CSO Questcor Pharmaceuticals

Dr. Andrew Mulberg

Ex Deputy Director FDA, GI Division
Portfolio Leader (J&J)

Dr. Mehdi Bouhaddou

Postdoctoral Scholar, Cellular Molecular
Pharmacology School of Medicine, UCSF

Dr. Kevin Grimes

Director, SPARK program, Stanford
Professor, Department of Chemical and Systems Biology

Dr. Mridul Mehta, PhD

15-year leader solving problems using data science and algorithms, including AI/ML

Jacqueline Fabius

Chief Operating Officer for the Quantitative Biosciences Institute (QBI) at UCSF

Mike Cassidy

Mike Cassidy was recently the CEO of Apollo Fusion, Inc. and a Vice President at Google.

Jared Friedman

Jared is Managing Director, Software and Group Partner at YC. He was cofounder of Scribd, which was funded by Y Combinator and grew to be one of the top 100 sites on the web. Jared previously worked at a pioneering AI company and studied computer science at Harvard.